Approach to the rehabilitation of spasticity and neuromuscular disorders in children

Neurologic Clinics

Volumn 21, Issue 4, 2003, Pages 853-881

  Tilton, Ann Henderson ^a  

^a CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BENZATROPINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; DANTROLENE; DIAZEPAM; GLYCOPYRRONIUM BROMIDE; SCOPOLAMINE; TIZANIDINE;

ADOLESCENT; BEHAVIOR THERAPY; CEREBRAL PALSY; CHILD; CHILD NUTRITION; CHILDHOOD DISEASE; COGNITIVE DEFECT; CONSTIPATION; DIARRHEA; DORSAL RHIZOTOMY; DUCHENNE MUSCULAR DYSTROPHY; FEEDBACK SYSTEM; GASTROINTESTINAL DISEASE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HYPERSALIVATION; INJECTION SITE; IRRITABILITY; JOINT CONTRACTURE; MASTICATION; MICTURITION DISORDER; MUSCLE HYPOTONIA; MUSCLE WEAKNESS; NAUSEA; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; REHABILITATION MEDICINE; REVIEW; SCOLIOSIS; SIDE EFFECT; SOCIAL WORK; SPASTICITY; SPEECH THERAPY; SPINAL MUSCULAR ATROPHY; SUBMANDIBULAR GLAND; TREATMENT PLANNING; URINE RETENTION; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA;

EID: 0142043294     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(03)00066-5     Document Type: Review

References (133)

1. Lance JW. Spasticity: disordered motor control. In: Feldman RG, Young RR, Roella WP, editors. Spasticity: disordered motor control. Chicago: Yearbook Medical; 1980. p. 485-94.
2. Sherrington CS. Decerebrate rigidity an reflex coordination of movement. J Physiol 1898;22:319-22.
3. Young RR. Spasticity: a review. Neurology 1994;44(Suppl 9): S12-20.
4. Burke D. Spasticity as an adaption to pyramidal tract injury. Adv Neurol 1988;47:401-23.
5. Katz RT, Rymer WZ. Spastic hypertonia: mechanisms and measurements. Arch Phys Med Rehabil 1989;70:144-55.
6. Mayer NH. Clinicophysologic concepts of spasticity and motor dysfunction in adults with an upper motorneuron lesion. Muscle Nerve 1997;70(Suppl 9):S1-13.
7. Herman R. The myotactic reflex: clinicophysiological aspects of spasticity and contracture. Brain 1970;93:273-312.
8. Hufschmidt A. Chronic transformation of muscle in spasticity: a peripheral contribution to increased tone. J Neurol Neurosurg Psychiatry 1985;48:676-85.
9. Carr LJ, Harrison LM, Evans AL, Stephens J. Patterns of central motor reorganization in hemiplegic cerebral palsy. Brain 1993;116:1223-47.
10. Evans AL, Harrison LM, Stephens JA. Cutaneomuscular reflexes recorded from the first dorsal interosseous muscle of children with cerebral palsy. Dev Med Child Neurol 1987;33:541-51.
11. Gibbs J, Harrison LM, Stephens JA, Evans AL. Cutaneomuscular reflex responses recorded from the lower limb in children and adolescents with cerebral palsy. Dev Med Child Neurol 1999;41:456-64.
12. Mayston MJ, Harrison LM, Stephens JA. Associated reactions and associated movements. Soc Neurosci 1995;21:172.
13. Mayston MJ. People with cerebral palsy: effects of and perspectives for therapy. Neural Plast 2001;8(1):51-69.
14. Gordon AM, Duff SV. Relation between clinical measures and fine manipulative control in children with hemiplegic cerebral palsy. Dev Med Child Neurol 1999;41:586-91.
15. Eliasson AC, Gordon AM, Forssberg H. Tactile control of isometric fingertip forces during grasping and lifting objects of children with cerebral palsy. Dev Med Child Neurol 1995;37:72-84.
16. Berger W, Quintern J, Dietz V. Pathophysiology of gait in children with cerebral palsy. Electroencephalogr Clin Neurophysiol 1982;53:538-48.
17. Mayston MJ, Harrison LM, Stephens JA. Co-contraction of antagonist muscles during development and in children with cerebral palsy. J Physiol 1996;494:67.
18. Haas BM, Bergstrom E, Jamous A, Bennie A. The inter rater reliability of the original and of the modified ashworth scale for the assessment of spasticity in patients with spinal cord injury. Spinal Cord 1996;34:560-4.
19. Tardieu G, Tardieu C, Colbeau-Justin P, Bret MD. Effects of muscle length on an increased stretch reflex in children with cerebral palsy. J Neurol Neurosurg Psychiatry 1982;45:348-52.
20. Russell DJ, Rosenbaum PL, Cadman DT, Gowland C, Hardy S, Jarvis S. The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol 1989;31:341-52.
21. Boyce WF, Gowland C, Rosenbaum PL, et al. Gross motor performance measure for children with cerebral palsy: study design and preliminary findings. Can J Public Health 1992;83(Suppl 2):S34-40.
22. Landau WM. Spasticity: the fable of a neurologic demon and the emperor's new therapy. Arch Neurol 1974;31:217-9.
23. Barry MJ. Physical therapy interventions for patients with movement disorders due to cerebral palsy. J Child Neurol 1996;11:S51-60.
24. Russman BS, Romness M. Neurorehabilitation for the child with cerebral palsy. In: Miller G, Clark GD, editors. The cerebral palsies, causes, consequences, and management Boston: Butterworth-Heinemann; 1998. p. 321-32.
25. Bobath B. The very early treatment of cerebral palsy. Dev Med Child Neurol 1996;9:373-93.
26. Palmer FB, Shapiro BK, Wachtel RC. The effects of physical therapy on cerebral palsy a controlled trial in infants with spastic diplegia. N Engl J Med 1988;318:803-8.
27. Scherzer AL, Mike V, Jolson J. Physical therapy as a determinant of change in the cerebral palsied infant. Pediatrics 1976;58:47-52.
28. Gracies JM, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part I: local treatments. Muscle Nerve 1997;20(Suppl 6):S61-91.
29. Young RR, Delwaide PJ. Drug therapy: spasticity (first of two parts). N Engl J Med 1981;304(1):28-33.
30. Haslam RH, Walcher JR, Leitman PS. Dantrolene sodium in children with spasticity. Arch Phys Med Rehabil 1974;55:384-8.
31. Joynt RL, Leonard JA. Dantrolene sodium suspension in treatment of spastic cerebral palsy. Dev Med Child Neurol 1980;22:755-67.
32. Katz RT. Management of spasticity. Am J Phys Med Rehabil 1988;67(3):108-16.
33. Engle HA. The effects of diazepam (valium) in children with cerebral palsy: a double blind study. Dev Med Child Neurol 1966;8:661-7.
34. Milla PJ, Jackson ADM. A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1977;5:398-404.
35. Pranzatelli MR. Oral pharmacotherapy for the movement disorders of cerebral palsy. J Child Neurol 1996;11 (Suppl 1):S13-22.
36. Young RR, Delwaide PJ. Drug therapy: spasticity (second of two parts). N Engl J Med 1981;304(2):96-9.
37. Russman BS, Tilton AH, Gormley ME Jr. Cerebral palsy: a rational approach to a treatment protocol and the role of botulinum toxin in treatment. In: Mayer N, Simpson DM, editors. Spasticity-etiology, evaluation, management and the role of botulinium toxin. New York: We Move; 2002.
38. Yablon S. Botulinum neurotoxin intramuscular chemodenervation-role in the management of spastic hypertonia and related motor disorders. Phys Med Rehabil Clin N Am 2001;12(4):833-74.
39. Koman LA, Mooney III JF, Smith BP, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum-a toxin: preliminary investigation. J Pediatr Orthop 1993;13(4):489-95.
40. Boyd RN, Hayes RM. Current evidence for the use of botulinum toxin a in the management of children with cerebral palsy:a systematic review. Eur J Neurol 2001;6(Suppl 5):1-20.
41. Flett PJ, Stern LM, Waddy H, Connell TM, Seeger JD, Gibson SK. Botulinum toxin a versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Pediatr Child Health 1999.
42. Baker R. Group EDDRCS. Botulinum toxin a (dysport) for the treatment of dynamic equinus spasticity associated with cerebral palsy: results of double blind, placebo-controlled, dose ranging study. Gait Posture 2000;12:64-5.
43. Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK. Botulinum toxin a in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 1997;39:185-93.
44. Autti-Ramo I, Larsen A, Peltonen J, Taimo A, von Wendt L. Botulinum toxin injection as an adjunct when planning hand surgery in children with spastic hemiplegia. Neuropediatrics 2000;31(1):4-8.
45. Boyd RN, Graham JE, Nattrass GR, Graham HK. Medium-term response characterisation and risk factor analysis of botulinum toxin type a in the management of spasticity in children with cerebral palsy. Eur J Neurol 1999;6:S37-45.
46. Delgado MR. The use of botulinum toxin type a in children with cerebral palsy: a retrospective study. Eur J Neurol 1999;6(Suppl 4):S11-8.
47. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: general and regional treatments. Muscle Nerve 1997;20(Suppl 6):S92-120.
48. Albright AL, Barry MJ, Fasick P, Barron W, Shultz B. Continous intrathecal baclofen infusion for symptomatic generalized dystonia. Neurosurgery 1996;181(5):934-9.
49. Grabb PA, Guin-Renfroe S, Meythaler JM. Midthoracic catheter tip placement for intrathecal baclofen administration in children with quadriparetic spasticity. Neurosurgery 1999;45(4):833-7.
50. Van Schaeybroeck P, Nuttin B, Lagae L, Schrijvers E, Borghgraef C, Feys P. Intrathecal baclofen for intractable cerebral spasticity: a prospective placebo-controlled, double-blind study. Neurosurgery 2000;46:603-12.
51. Albright AL. Intrathecal baclofen in cerebal palsy movement disorders. J Child Neurol 1996;11:S29-35.
52. Damiano DL, Kelly LE, Vaughan CL. Effects of quadriceps strengthening in crouched gait in children with spastic diplegia. Phys Ther 1995;75:658-67.
53. Gilmartin R, Bruce D, Abbott R, Krach L, Ward J, Bloom K. Intrathecal baclofen for the management of spastic cerebral palsy: multicenter trial. J Child Neurol 2000;15:71-7.
54. Albright AL. Baclofen in the treatment of cerebral palsy. J Child Neurol 1996;11(2):77-83.
55. Albright AL, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA 1991;265:1418-22.
56. Alemeida GL, Campbell SK, Girolami GL, Penn RD, Corcos DM. Multidimensional assessment of motor function in a child with cerebal palsy following intrathecal administration of baclofen. Phys Ther 1997;77(7):751-64.
57. Medtronic. Intrathecal baclofen therapy: clinical reference guide for spasticity management. Minneapolis (MN): Medtronic; 1996.
58. Green LB, Nelson VS. Death after withdrawal of intrathecal baclofen: case report and literature review. Arch Phys Med Rehabil 1999;80:1600-4.
59. Peacock WJ, Staudt L. Selective posterior rhizotomy: history and results. Neurosurgery 1989;4(2):403-8.
60. Engsberg JR, Ross SA, Park TS. Changes in ankle spasticity and strength following selective dorsal rhizotomy and physical therapy for spastic cerebral palsy. J Neurosurg 1999;91(5):727-32.
61. Chicoine MR, Park TS, Voger GP, Kaufman BA. Predictors of ability to walk after selective dorsal rhizotomy in children with cerebral palsy. Neurosurgery 1996;38(4):711-4.
62. Lazareff JA, Garcia-Mendez MA, De Rosa R, Olmstead C. Limited (L4-S1, L5-S1) selective dorsal rhizotomy for reducing spasticity in cerebral palsy. Acta Neurochir (Wien) 1999;141:743-51.
63. McLaughlin JF, Bjornson KF, Astley SJ, et al. Selective dorsal rhizotomy: efficacy and safety in an investigator-masked randomized clinical trial. Dev Med Child Neurol 1998;40:220-32.
64. Wright F, Sheil EM, Drake JM, Wedge JH, Naumann S. Evaluation of selective dorsal rhizotomy for the reduction of spasticity in cerebral palsy: a randomized control study. Dev Med Child Neurol 1998;40:239-47.
65. Lin JP. Dorsal rhizotomy and physical therapy. Dev Med Child Neurol 1998;40:219.
66. Crysdale WS. Management options for the drooling patient. Ear Nose Throat J 1989;68:820-30.
67. Bachrach SJ, Walters RS, Trzcinski K. Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. Clin Pediatr 1998;37:458-90.
68. Bothwell JE, Clarke K, Dooley JM, et al. Botulinum toxin a as a treatment for excessive drooling in children. Pediatr Neurol 2002;27(1):18-22.
69. Blasco PA, Allaire JH. Drooling in the developmentally disabled: management practices and recommendations. Dev Med Child Neurol 1992;34:849-62.
70. Ekedahl C. Surgical treatment of drooling. Acta Otolaryngol 1974;77:215-20.
71. Makhani JS. Dribbling of saliva in children with cerebral palsy and its management. Indian J Pediatr 1974;41:272-7.
72. Lespargot A, Langevin MF, Muller S, Guillemont S. Swallowing disturbances associated with drooling in cerebral palsied children. Dev Med Child Neurol 1993;35:298-304.
73. Klem C, Mair EA. Four-duct ligation: a simple and effective treatment for chronic aspiration from sialorrhea. Arch Otolaryngol Head Neck Surg 1999;125(7):796-800.
74. Suskind DL, Tilton AH. Clinical study of botulinum-a toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope 2002;112:73-81.
75. Harris SR, Purdy AH. Drooling and its management in cerebral palsy. Dev Med Child Neurol 1987;29:805-14.
76. Brodtkorb E, Wyzocka-Bakawska MM, Lillevold PE, et al. Transdermal scopolamine in drooling. J Ment Defic Res 1988;32:233-7.
77. Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M. Treatment of sialorrhea with glycopyrrolate a double-blind, dose-ranging study. Arch Pediatr Adolesc Med 2000;154:1214-8.
78. Blasco PA, Stansbury JC. Glycopyrrolate treatment of chronic drooling. Arch Pediatr Adolesc Med 1996;150:932-5.
79. Glass LW, Nobel GL, Vecchione TR. Treatment of uncontrolled drooling by bilateral excision of submandibular glands and parotid duct ligations. Plast Reconstr Surg 1997;59:791-8.
80. Burton MJ. The surgical management of drooling. Dev Med Child Neurol 1991;33:1110-6.
81. Webb K, Reddihough DS, Johnson H, Bennett CS, Byrt T. Long-term outcome of saliva-control surgery. Dev Med Child Neurol 1995;37:755-62.
82. Wilkie TF, Broady GS. The surgical treatment of drooling: a ten year review. Plast Reconstr Surg 1977;59:791-8.
83. Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses n otolaryngology. Laryngoscope 2001;11(2):218-26.
84. Kim KS, Kim SS, Yoon JH, Han JM. The effects of botulinum toxin type a injections for intrinsic rhinitis. J Laryngol Otol 1998;112:248-51.
85. Shaari CM, Wu B, Biller HF, Chuang S, Sanders I. Botulinum toxin decreases salivation from canine submandibular glands. Otolaryngol Head Neck Surg 1998;118:452-7.
86. Giess R, Naumann M, Werner E, et al. Injections of botulinum toxin a into the salivary glands improve sialorrhea in amytrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000;69(1):121-3.
87. Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin a as treatment for drooling saliva in, PD. Neurology 2000;54(1):244-7.
88. Shaari CM, Sanders I, Wu B, Biller HF. Rhinorrhea is decreased in dogs after nasal application of botulinum toxin. Otolaryngol Head Neck Surg 1995;112:566-7.
89. Naumann M, Hofmann U, Bergmann I, et al. Focal hyperhydrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 1998;134:301-4.
90. Jongerius PH, Rotteveel JJ, van der Hoogen F, Joosten F, van Hulst K, Gabreel FJ. Botulinum toxin a: a new option for treatment of drooling in children with cerebral palsy. presentation of a case. Eur J Pediatr 2001;160:509-12.
91. Russman BS, Tilton A, Gormley ME Jr. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve 1997;160(Suppl 6):S181-93.
92. Scott OM, Hyde SA, Goddard C. Prevention of deformity in Duchenne muscular dystrophy. a prospective study of passive stretching and splintage. Physiotherapy 1981;67:177-80.
93. McDonald CM. Physical activity, health impairments, and disability in neuromuscular disease. Am J Phys Med Rehabil 2002;81(Suppl 11):S108-20.
94. Dobkins BH, editor. Neurologic rehabilitation. Contemporary neurology series. Philadelphia: F.A. Davis; 1996.
95. Vignos PJ Jr, Watkins MP. The effect of exercise in muscular dystrophy. JAMA 1966;197:121-6.
96. Russman BS. Rehabilitation of the child with a neuromuscular disorder. In: Jones HR, De Vivo DC, Darras BT, editors. Neuromuscular disorders of infancy, childhood, and adolescence. Philadelphia: Butterworth Heinemann; 2003. p. 1275-8.
97. Yasuda YL, Bowman K, Hsu JD. Mobile arm supports: criteria for successful use in muscle disease patients. Arch Phys Med Rehabil 1986;67:253-6.
98. Tilton AH, Miller MD, Khoshoo V. Nutrition and swallowing in pediatric neuromuscular patients. Semin Pediatr Neurol 1998;5(2):106-15.
99. Willig TN, Paulus J, Lacau Saint Guily J, Beon C, Navarro J. Swallowing problems in neuromuscular disorders. Arch Phys Med Rehabil 1994;75:1175-81.
100. Ingervall B, Helkimo E. Masticatory muscle force and facial morphology in man. Arch Oral Biol 1978;23:203-6.
101. Willig TN, Carlier L, Legrand M, Riviere H, Navarro J. Nutritional assessment in duchenne muscular dystrophy. Dev Med Child Neurol 1993;35:1074-82.
102. Griffiths RD, Edwards RHT. A new chart for weight control in duchenne muscular dystrophy. Arch Dis Child 1988;63:1256-8.
103. Edwards RH, Round JM, Jackson MJ, Griffiths RD, Lilburn MF. Weight reduction in boys with muscular dystrophy. Dev Med Child Neurol 1984;26:384-90.
104. Hankard R, Gottrand F, Turck D, Carpentier A, Romon M, Farriaux JP. Resting energy expenditure and energy substrate utilization in children with duchenne muscular dystrophy. Pediatr Res 1996;40:29-33.
105. Jaffe KM, McDonald CM, Ingman E, Haas J. Symptoms of upper gastrointestinal dysfunction in duchenne muscular dystrophy: case control study. Arch Phys Med Rehabil 1990;71:742-4.
106. Kilman W, Goyal R. Disorders of pharyngeal and upper esophageal sphincter motor function. Arch Intern Med 1976;136:592-601.
107. Lewis D, Khoshoo V, Pencharz P, Golladay ES. Impact of nutritional rehabilitation on gastroesophageal reflux in neurologically impaired children. J Pediatr Surg 1994;29:167-9.
108. Bach JR, Zhitnikov S. The management of neuromuscular ventilatory failure. Semin Pediatr Neurol 1998;5:92-105.
109. Bach JR, Alba AS. Management of chronic alveolar hypoventilation by nasal ventilation. Chest 1990;97:52-7.
110. Gozal D. Pulmonary manifestations of neuromuscular disease with special reference to duchenne muscular dystrophy and spinal muscular atrophy. Pediatr Pulmonol 2001;31:89-90.
111. McDonald CM, Abresch RT, Carter C, Fowler WM Jr, Johnson ER, Kilmer DD. Profiles of neuromuscular diseases: duchenne muscular dystrophy. Am J Phys Med Rehabil 1995;74(Suppl 5):S93-103.
112. Miller WF. Rehabilitation of patients with chronic obstructive lung disease. Med Clin North Am 1967;51:349-61.
113. Rochester DF, Braun NMT. Determinant of maximal inspiratory pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1985;132:42-7.
114. Inkley SR, Oldenberg FC, Vignos PJ Jr. Pulmonary function in duchenne muscular dystrophy related to stage of disease. Am J Med 1974;56:297-306.
115. Bach JR, Saporito LR. Criteria for extubation and tracheostomy tube removal for patients with ventilatory failure: a different approach to weaning. Chest 1996;110:1566-71.
116. Redding GJ, Okamoto G, Guthrie R, Rollevson D, Milstein JM. Sleep patterns in nonambulant boys with duchenne muscular dystrophy. Arch Phys Med Rehabil 1985;66:818-21.
117. Bach JR, Rajarman R, Ballanger F, et al. Neuromuscular ventilatory insufficiency: the effect of home ventilation use vs.oxygen therapy on pneumonia hospitalization rates. Am J Phys Med 1998;77:8-19.
118. Smith EI. Bioethics in pediatric neuromuscular disease. Semin Pediatr Neurol 1998;5:124-31.
119. Bach JR, Vega J, Majors J, Friedman A. Spinal muscular atrophy type 1 quality of life. Am J Phys Med Rehabil 2003;82:137-42.
120. Birch JG. Orthopedic management of neuromuscular disorders in children. Semin Pediatr Neurol 1998;5(2):78-91.
121. Shapiro F. Orthopedic treatment. In: Jones HR, De Vivo DC, Darras BT, editors. Neuromuscular disorders of infancy, childhood, and adolescence. Philadelphia: Butterworth Heinemann; 2003. p. 1251-73.
122. Bakker JP, de Groot IJ, Beckerman H, de Jong BA, Lankhorst GJ. The effects of knee-ankle-foot orthosis, in the treatment of duchenne muscular dystrophy: review of the literature. Clin Rehabil 2000;14(4):343-59.
123. Heckmatt J, Dubowitz V, Hyde SA, et al. Prolongation fo walking in duchenne muscular dystrophy with lightweight orthoses: review of 57 cases. Dev Med Child Neurol 1985;27:149-54.
124. Smith SE, Green NE, Cole RJ, Robinson JD, Fenichel GM. Prolongation of ambulation in children with duchenne muscular dystrophy by subcutaneous lower limb tenotomy. J Pediatr Orthop 1993;13:336-40.
125. Bonnet L, Burgot D, Bonnard C, Glorion B. Surgery of the lower limbs in Duchenne muscular dystrophy. French J Orthop Surg 1991;5:160-8.
126. Goertzen M, Baltzer A, Voit T. Clinical results of early orthopaedic management in duchenne muscular dystrophy. Neuropediatrics 1995;26(5):257-9.
127. Rideau Y, Glorion B, Duport G. Prolongation of ambulation in the muscular dystrophies. Acta Neurol (Napoli) 1983;38:390-7.
128. Forst J, Forst R. Lower limb surgery in duchenne muscular dystrophy. Neuromuscul Disord 1999;9(3):176-81.
129. Smith AD, Koreska J, Mosley CF. Progression of scoliosis in duchenne muscular dystrophy. J Bone Joint Surg 1989;71:1066-74.
130. Cambridge W, Drenman JC. Scoliosis associated with duchenne muscular dystrophy. J Pediatr Orthop 1987;7:436-40.
131. Bentley G, Haddad F, Bull TM, Seingry D. The treatment of scoliosis in muscular dystrophy using modified luque and harrington-luque instrumentation. J Bone Joint Surg 2001;83:22-8.
132. Evans GA, Drenman JC, Russman BS. Functional classification and orthopedic management of spinal muscular atrophy. J Bone Joint Surg 1981;63:516-22.
133. Merlini L, Granata C, Bonfiglioli S. Scoliosis in spinal muscular atrophy: natural history and management. Dev Med Child Neurol 1989;31:501-8.